A phase I study of DB-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) in adult patients with refractory or metastatic solid malignancies

Trial Profile

A phase I study of DB-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) in adult patients with refractory or metastatic solid malignancies

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Aug 2009

At a glance

  • Drugs AR 67 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Arno Therapeutics
  • Most Recent Events

    • 18 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Jun 2008 Added Arno Therapeutics as an affiliate and sponsor, from Arno Therapeutics media release.
    • 04 Jun 2008 Preliminary phase 1 data are available, according to a media release from Arno Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top